SavedAdd your journal

Journals / Kırıkkale Üniversitesi Tıp Fakültesi Dergisi / 2021 / Cilt: 23 Sayı: 2

Gamma Glutamyl Transpeptidase Effect in Testicular Tumor; Is a New Biomarker Born?

TESTİS TÜMÖRÜNDE GAMA GLUTAMİL TRANSPEPTİDAZ ETKİSİ; YENİ BİR BİYOBELİRTEÇ Mİ DOĞUYOR?

Batuhan Ergani(Beyhekim Eğitim ve Araştırma Hastanesi)0000-0002-4667-855X
Mehmet Yalçın(Şanlıurfa Eğitim ve Araştırma Hastanesi)0000-0001-9943-7453
Mert Hamza Özbilen(Tepecik Eğitim ve Araştırma Hastanesi, İzmir)0000-0002-5733-6790
Çağdaş Bildirici(Tepecik Eğitim ve Araştırma Hastanesi, İzmir)0000-0002-4220-8147
Erkin Karaca(Tepecik Eğitim ve Araştırma Hastanesi, İzmir)0000-0002-9123-4069
Erkan Aravacık(Tepecik Eğitim ve Araştırma Hastanesi, İzmir)0000-0002-6791-4566
Hayal Boyacıoğlu(EGE ÜNİVERSİTESİ, FEN FAKÜLTESİ, İSTATİSTİK BÖLÜMÜ)0000-0002-2990-4383
Yusuf Özlem İlbey(Tepecik Eğitim ve Araştırma Hastanesi, İzmir)0000-0002-1483-9160
Pages
309–317
Publication Date
2021-08-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objective: The aim of this study is to investigate the use of serum gamma-glutamyl transpeptidase level as a biomarker especially in seminomatous subtype disease in testicular tumor patients and to investigate the superiority of biomarkers currently in use, and to examine the role of serum gamma-glutamyl transpeptidase levels in chemotherapy response, maintenance and nephrotoxicity in patients receiving cisplatin-based chemotherapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to investigate the use of serum gamma-glutamyl transpeptidase level as a biomarker especially in seminomatous subtype disease in testicular tumor patients and to investigate the superiority of biomarkers currently in use, and to examine the role of serum gamma-glutamyl transpeptidase levels in chemotherapy response, maintenance and nephrotoxicity in patients receiving cisplatin-based chemotherapy.
📊
Key Findings & Data:Objective: The aim of this study is to investigate the use of serum gamma-glutamyl transpeptidase level as a biomarker especially in seminomatous subtype disease in testicular tumor patients and to investigate the superiority of biomarkers currently in use, and to examine the role of serum gamma-glutamyl transpeptidase levels in chemotherapy response, maintenance and nephrotoxicity in patients receiving cisplatin-based chemotherapy.
💡
Conclusion & Impact:Objective: The aim of this study is to investigate the use of serum gamma-glutamyl transpeptidase level as a biomarker especially in seminomatous subtype disease in testicular tumor patients and to investigate the superiority of biomarkers currently in use, and to examine the role of serum gamma-glutamyl transpeptidase levels in chemotherapy response, maintenance and nephrotoxicity in patients receiving cisplatin-based chemotherapy.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Biyobelirteç · Gama-glutamil transpeptidaz · Testis tümörü.

Abstract

Objective: The aim of this study is to investigate the use of serum gamma-glutamyl transpeptidase level as a biomarker especially in seminomatous subtype disease in testicular tumor patients and to investigate the superiority of biomarkers currently in use, and to examine the role of serum gamma-glutamyl transpeptidase levels in chemotherapy response, maintenance and nephrotoxicity in patients receiving cisplatin-based chemotherapy.

Özet

Amaç: Bu çalışmanın amacı testis tümörü hastalarında serum gama-glutamil transpeptidaz düzeyinin özellikle seminomatöz alt tipteki hastalıkta bir biyobelirteç olarak kullanılabilirliğinin, mevcut kullanımda olan biyobelirteçlere üstünlüğünün araştırılması ile sisplatin temelli kemoterapi alan hastalarda serum gama-glutamil transpeptidaz seviyelerinin kemoterapi yanıtı, devamı ve nefrotoksisitedeki rollerini incelemektir.

🔖

Cite This Article

Ergani, B., Yalçın, M., Özbilen, M. H., Bildirici, Ç., Karaca, E., Aravacık, E., Boyacıoğlu, H., İlbey, Y. Ö., *, B. E. (2021). Gamma Glutamyl Transpeptidase Effect in Testicular Tumor; Is a New Biomarker Born?. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, Cilt: 23 Sayı: 2, 309–317. https://doi.org/10.24938/kutfd.900045

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (27)

  1. Vaitukaitis JL, Braunstein GD, Ross GT. A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. Am J Obstet Gynecol. 1972;113:751.
  2. Waldmann TA, Mclntire KR. The use of a radioimmunoassay for alphafetoprotein in the diagnosis of malignancy. Cancer. 1974;34:1510.
  3. Javadpour N, Mclntire KR, Waldmann TA. Immunochemical determination of human chorionic gonadotropin (HCG) and alphafetoprotein (AFP) in sera and tumors of patients with testicular cancer. Null Cancer Inst Monogr. 1978;49:209-13.
  4. Rosen SW, Javadpour N, Calvert I, Kaminska J. Pregnancy-specific B glycoprotein (SP) is increased in certain non-seminomatous germ cell tumors. J Natl Cancer Inst. 1979;62:1439.
  5. Kohn J, Orr AH, McElwain TJ, Bentall M, Peckham MJ. Serum alpha-feto-protein in patients with testicular tumors. Lancet. 1976;2:433-6.
  6. Lange PH, Fraley EE. Serum alpha-fetoprotein and human chorionic gonadotropin in the treatment of patients with testicular tumors. Urol Clin Norrh Am. 1977;4:393.
  7. Wıllemse P, Sleıjfer D, Schraffordt K, De Bruijn HW, Oosterhuis JW, Brouwers TM et al. Tumor markers in patients with non-seminomatous germ cell tumors of the testis. Oncodeu Biol Med. 1981;2:117-28.
  8. Bosl JG, Geller İN, Cirrincione MS, Nisselbaum J, Vugrin D, Whitmore Jr WF et al. Serum tumor markers in patients with metastatic germ cell tumors of the testis. Am J Med. 1983;75:29-35.
  9. Perrin P, Ardiet C, Pommatau F. Tumor markers in germinal testis tumors. Acta Urologica Belgica. 1982;53:212-22.
  10. Scardino P, Cox H, Waldmann T, Mcintire KR, Mittemeyer B, Javadpour N. The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis. J Ural. 1977;118:994-9.
  11. Fraley E, Lange P, Kennedy B. Germ cell testicular cancer in adults. N Engl J Med. 1979;301:1370-7.
  12. Fishman WH, lnglis NR, Stolbach CC, Krant MJ. A serum alkaline phosphatase isoenzyme of human neoplastic cell origin. Cancer Res. 1968;28:150.
  13. Wahren B, Holmgren PA, Stigbrand T. Placental alkaline phosphatase, alphafetoprotein and carcinoembryonic antigen in testicular tumors: Tissue typing by means ofcytologic smear. Intl J Cuncer. 1979;24:749.
  14. Laishes BA, Ogawa K, Roberts E, Farber E. Gamma-glutamyl transpetidase: A positive marker for cultured rat liver cells derived from putative premalignant and malignant lesions. J Nafl Cancer Inst. 1978;60:1009.
  15. Krishnaswamy PR, Tate S, Meister A. Gamma, glutamyl transpeptidase of human seminal fluid. Liye Science. 1977;20:681.
  16. Galanski M. Recent developments in the field of anticancer platinum complexes. Recent Patents Anticancer Drug Discov. 2006;1:285-95.
  17. Kostova I. Platinum complexes as anticancer agents. Recent Patents Anticancer Drug Discov. 2006;1:1-22.
  18. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990;8:1777-81.
  19. Segelov E, Campbell J, Ng M, Tattersall M, Rome R, Free K et al. Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience. J Clin Oncol. 1994;12:378-84. 20. Chu G. Cellular responses to cisplatin. J Biol Chem. 1994;269:787-90.
  20. Yao X, Panichpisal K, Kirtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334:115-24.
  21. Hanigan MH, Lykissa ED, Townsend DM, Ou CN, Barrios R, Lieberman MW. Gama glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. Am J Pathol. 2001;159:1889-94.
  22. Hanigan MH, Gallagher BC, Taylor PT Jr, Large MK. Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res. 1994;54:5925-9.
  23. Hanigan MH, Frierson HF Jr. Immunohistochemical detection of g-glutamyl transpeptidase in normal human tissue. J Histochem Cytochem. 1996;44:1101-8.
  24. Javadpour N. Multiple biochemical tumor markers in seminoma. Cancer. 1983;52:887-9.
  25. Bedük Y, Yurdakul T, Adsan Ö, Yaman LS, Renda N. Testis tümörlerinde multipl serum tümör belirleyicileri (ön rapor). T Klin Araştırma. 1991;9:217-20.
  26. Satoh M, Aoki Y, Tohyama C. Protective role of metallothionein in renal toxicity of cisplatinum. Cancer Chemother Pharmacol. 1997;40:358-62.
  27. Wainford RD, Weaver RJ, Stewart KN, Brown P, Hawksworth GM. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology. 2008;249:184-93.